Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 21339742 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Takahashi F, et al. (2011) Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib. Oncogene 30, 3084-95 21339742
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell), MDA-MB231 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
LY294002 EGF inhibit treatment-induced increase
lapatinib EGF inhibit treatment-induced increase
Epiregulin (human) increase Epiregulin siRNA decreases
NRG1 (human) increase NRG1 siRNA inhibits
BTG2 (human) decrease
BTG2 (human) increase MDA-MB-231 cells
lapatinib decrease
BTG2 (human) decrease BTG2 siRNA increases
EGF BTG2 (human) increase
HRas (human), BTG2 (human) increase
lapatinib decrease

Y1110-p - EGFR (human)
Orthologous residues
EGFR (human): Y1110‑p, EGFR iso5 (human): , EGFR (mouse): Y1110‑p, EGFR (rat): Y1109‑p, EGFR (pig): Y1109‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell), MDA-MB231 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BTG2 (human) no change compared to control
EGF BTG2 (human) increase
HRas (human) BTG2 (human) no change compared to control
lapatinib decrease

Y1221-p - HER2 (human)
Orthologous residues
HER2 (human): Y1221‑p, HER2 iso2 (human): Y611‑p, HER2 (mouse): Y1222‑p, HER2 (rat): Y1223‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell), MDA-MB231 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BTG2 (human) decrease BTG2 siRNA increases
EGF BTG2 (human) increase
HRas (human), BTG2 (human) increase
lapatinib decrease

Y1222-p - HER2 (human)
Orthologous residues
HER2 (human): Y1222‑p, HER2 iso2 (human): Y612‑p, HER2 (mouse): Y1223‑p, HER2 (rat): Y1224‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell), MDA-MB231 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BTG2 (human) decrease BTG2 siRNA increases
EGF BTG2 (human) increase
HRas (human), BTG2 (human) increase
lapatinib decrease

Y1289-p - HER3 (human)
Orthologous residues
HER3 (human): Y1289‑p, HER3 iso2 (human): , HER3 (mouse): Y1286‑p, HER3 (rat): Y1286‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell), MDA-MB231 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BTG2 (human) decrease
BTG2 (human) increase MDA-MB-231 cells
lapatinib decrease
BTG2 (human) decrease BTG2 siRNA increases
EGF BTG2 (human) increase
HRas (human), BTG2 (human) increase
lapatinib decrease


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.